insights_auto
Why is ONC down 3.82%?
Dive Deeperchevron_right
ONC:NASDAQ
BeOne Medicines AG
$350.13
arrow_downward
-3.82%(-13.89) 1D
$343.01
arrow_downward
-2.03% (-7.12)todayPre-market
Closed: Oct 8, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
$351.94
High
$355.01
Low
$340.44
Mkt. cap
44.00B
Avg. vol.
366.17K
Volume
484.00
52-wk high
$385.22
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
Open
$351.94
High
$355.01
Low
$340.44
Mkt. cap
44.00B
Avg. vol.
366.17K
Volume
484.00
52-wk high
$385.22
52-wk low
$253.95
Beta
0.61
Shares outstanding
109.79M
No. of employees
12K
News stories
From web sources and news partners
AD HOC NEWS
·
15 hours ago
RBC raises target for BeOne Medicines stock to USD 459.00
TipRanks
·
17 hours ago
BeOne Medicines Advances BGB-43395 With New Drug Interaction Study Update
MarketBeat
·
18 hours ago
BeOne Medicines (NASDAQ:ONC) Stock Falls 5.8% - Here's What Happened
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorBiotechnology
Websitebeonemedicines.com